← Back to Search

Morphine sulfate - Visit 1 for Pulmonary Arterial Hypertension

Phase 2
Waitlist Available
Led By John Granton, MD, FRCPC
Research Sponsored by John Granton
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the distance travelled during each 6 minute walk will be determined at completion of the 6-minute walk test. the distance travelled during the 6-minute walk test will be recorded within 1 and 7 days of each other.
Awards & highlights

Study Summary

Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic. In one survey of 315 patients with PAH, sixty-eight percent had moderate or severe dyspnea on exertion and 40% had a profound and clinically significant deficit in quality of life. Palliative care is being increasingly investigated in life-limiting cardiovascular diseases to alleviate symptoms. In PAH, its implementation is frequently delayed until end-of-life. Opioids are a common palliative care intervention, however the efficacy and safety of opioids for symptom relief in PAH has not been evaluated.

Eligible Conditions
  • Pulmonary Arterial Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the distance travelled during each 6 minute walk will be determined at completion of the 6-minute walk test. the distance travelled during the 6-minute walk test will be recorded within 1 and 7 days of each other.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the distance travelled during each 6 minute walk will be determined at completion of the 6-minute walk test. the distance travelled during the 6-minute walk test will be recorded within 1 and 7 days of each other. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Borg Dyspnea Score
Secondary outcome measures
Change in 6-Minute Walk Distance

Trial Design

2Treatment groups
Active Control
Group I: Morphine sulfate - Visit 1Active Control1 Intervention
Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
Group II: Morphine sulfate - Visit 2Active Control1 Intervention
Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.

Find a Location

Who is running the clinical trial?

John GrantonLead Sponsor
John Granton, MD, FRCPCPrincipal InvestigatorUniversity Health Network, Toronto
1 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
John Granton 2017. "Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03401476.
All > Pulmonary Arterial Hypertension > High Blood Pressure
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top